126 related articles for article (PubMed ID: 3470543)
21. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
22. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.
Yoneda Y; Yoshida R
J Immunol; 1998 Jun; 160(12):6012-7. PubMed ID: 9637516
[TBL] [Abstract][Full Text] [Related]
23. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
25. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
Gordon LB; Nolan SC; Cserr HF; Knopf PM; Harling-Berg CJ
J Immunol; 1997 Sep; 159(5):2399-408. PubMed ID: 9278331
[TBL] [Abstract][Full Text] [Related]
26. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
[TBL] [Abstract][Full Text] [Related]
27. Induction of antitumor immunity by tumor cells treated with abrin.
Shionoya H; Arai H; Koyanagi N; Ohtake S; Kobayashi H; Kodama T; Kato H; Tung TC; Lin JY
Cancer Res; 1982 Jul; 42(7):2872-6. PubMed ID: 7083176
[TBL] [Abstract][Full Text] [Related]
28. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.
Yoshida R; Sanchez-Bueno A; Yamamoto N; Einaga-Naito K
J Immunol; 1997 Jul; 159(1):15-21. PubMed ID: 9200433
[TBL] [Abstract][Full Text] [Related]
29. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
30. Effect of beta-carotene and canthaxanthin on tert-butyl hydroperoxide-induced lipid peroxidation in murine normal and tumor thymocytes.
Palozza P; Luberto C; Ricci P; Sgarlata E; Calviello G; Bartoli GM
Arch Biochem Biophys; 1996 Jan; 325(2):145-51. PubMed ID: 8561491
[TBL] [Abstract][Full Text] [Related]
31. Vitamin A and tumor immunity.
Tomita Y; Himeno K; Nomoto K; Endo H; Hirohata T
Experientia; 1985 Jan; 41(1):92-3. PubMed ID: 3871403
[TBL] [Abstract][Full Text] [Related]
32. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
[TBL] [Abstract][Full Text] [Related]
33. Oral administration of Chlorella vulgaris augments concomitant antitumor immunity.
Tanaka K; Tomita Y; Tsuruta M; Konishi F; Okuda M; Himeno K; Nomoto K
Immunopharmacol Immunotoxicol; 1990; 12(2):277-91. PubMed ID: 2229925
[TBL] [Abstract][Full Text] [Related]
34. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
35. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
[TBL] [Abstract][Full Text] [Related]
36. Protective serum effects in tumor immunity.
Vaage J
Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
[TBL] [Abstract][Full Text] [Related]
37. Synergism between IFN-gamma and IL-1 alpha/beta in growth inhibition of an allografted tumor.
Takikawa O; Oku T; Yasui H; Yoshida R
J Immunol; 1993 Aug; 151(4):2070-6. PubMed ID: 8345196
[TBL] [Abstract][Full Text] [Related]
38. Influence of surgical removal and effect of levamisole on cytotoxic T-cell-mediated antitumor immunity in mice.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1983 Nov; 43(11):5120-5. PubMed ID: 6604572
[TBL] [Abstract][Full Text] [Related]
39. A time factor in the success or failure of immune rejection of transplanted tumors.
Vaage J
Cancer Res; 1977 Apr; 37(4):1064-7. PubMed ID: 844038
[TBL] [Abstract][Full Text] [Related]
40. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
Sobotková E; Nouza K
Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
